公开(公告)号：US20240123031A1

公开(公告)日：2024-04-18

申请号：US18254356

申请日：2021-11-24

Applicant: Bristol-Myers Squibb Company

Inventor： Edgar Davidson CHARLES ,  Shuyan DU ,  Giridhar S. TIRUCHERAI ,  George Harry KLINGER ,  Masayuki YAMAGUCHI ,  Diane Elizabeth SHEVELL

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/60

CPC classification number: A61K38/1825 ,  A61K9/0019 ,  A61K47/60

Abstract: The present disclosure provides a method of treating or preventing a disease or condition associated with fibrosis and/or diabetes in a subject in need thereof comprising subcutaneously administering to the subject one or more effective doses of a fibroblast growth factor 21 (FGF-21) polypeptide, e.g., FGF-21 conjugate, e.g., PEG-FGF-21.

公开(公告)号：US20240122857A1

公开(公告)日：2024-04-18

申请号：US17753657

申请日：2020-09-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jing TAO ,  Anisha PATEL ,  Umesh KESTUR ,  Admassu ABEBE ,  Divyakant Shantilal DESAI

IPC: A61K9/20 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/2077 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The present application is directed to a pharmaceutical composition comprising (R)—N-(4-chlorophenyl)-2-((1S, 4S)-4-(6-fluoroquinolin-4-yl) cyclohexyl) propanamide methane sulfonic acid salt that is resistant to salt disproportionation:

公开(公告)号：US20240109899A1

公开(公告)日：2024-04-04

申请号：US18264298

申请日：2022-02-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： BRIAN E. FINK ,  EMILY CHARLOTTE CHERNEY ,  LIPING ZHANG ,  JULIAN C. LO ,  GRETCHEN M. SCHROEDER ,  TRAM N. HUYNH ,  DONNA D. WEI ,  VIJAY T. AHUJA ,  CLAUDE A. QUESNELLE

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20240109888A1

公开(公告)日：2024-04-04

申请号：US18347703

申请日：2023-07-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Jie Chen ,  Carolyn Diane Dzierba ,  David B. Frennesson ,  Junqing Guo ,  Amy C. Hart ,  Xirui Hu ,  Michael E. Mertzman ,  Matthew Reiser Patton ,  Jianliang Shi ,  Steven H. Spergel ,  Brian Lee Venables ,  Yong-Jin Wu ,  Zili Xiao ,  Michael G. Yang

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof,




are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11945834B2

公开(公告)日：2024-04-02

申请号：US16978208

申请日：2019-03-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brian E. Fink ,  Zheming Ruan

IPC: C07H21/02 ,  C07K16/28

CPC classification number: C07H21/02 ,  C07K16/2818

Abstract: The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20240101666A1

公开(公告)日：2024-03-28

申请号：US18033200

申请日：2021-10-22

Applicant: Bristol-Myers Squibb Company

Inventor： Laurence David TOMS ,  Paul Andrew BASCIANO

IPC: C07K16/28 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K31/282 ,  A61K31/337 ,  A61K31/519 ,  A61K33/243 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507

Abstract: The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

公开(公告)号：US20240066123A1

公开(公告)日：2024-02-29

申请号：US18336889

申请日：2023-06-16

Applicant: Bristol-Myers Squibb Company

Inventor： Lori S. BURTON ,  William Ying ,  Nils Lonberg ,  Sudhir Chakravarthi ,  Pedro Smith

IPC: A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/28

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61J1/1412

Abstract: This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.

公开(公告)号：US20240051996A1

公开(公告)日：2024-02-15

申请号：US17943532

申请日：2022-09-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gardner S. CREECH ,  Mahboubeh KHEIRABADI ,  Martin D. EASTGATE ,  David S. NIRSCHL ,  Percy H. CARTER

IPC: C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/04 ,  C07K1/107 ,  C07K17/08

CPC classification number: C07K7/64 ,  C07C309/75 ,  C07C309/77 ,  C07D225/08 ,  C07K1/042 ,  C07K1/1077 ,  C07K17/08

Abstract: The disclosure is directed to the synthesis and improved methods for purifying macrocyclic peptides produced by solid phase peptide synthesis.

公开(公告)号：US20240050564A1

公开(公告)日：2024-02-15

申请号：US18271579

申请日：2022-01-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yu LIU ,  Sarah TANNENBAUM-DVIR

IPC: A61K39/395 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/7048 ,  A61K31/282 ,  A61P35/00

Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with lung cancer, such as small cell lung cancer, comprising administering to the subject various combinations of an anti-fucosyl-GM1 antibody, an immunomodulatory agent, such as a PD-1/PD-L1 antagonist, such as an antagonist anti-PD-1 or anti-PD-L1 antibody, carboplatin and etoposide.

公开(公告)号：US11884650B2

公开(公告)日：2024-01-30

申请号：US17743615

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D401/12

Abstract: There are disclosed compounds of the following formula I:




or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.